<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708054</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0790</org_study_id>
    <secondary_id>NCI-2020-13919</secondary_id>
    <secondary_id>2020-0790</secondary_id>
    <nct_id>NCT04708054</nct_id>
  </id_info>
  <brief_title>Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and&#xD;
      fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic&#xD;
      syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax,&#xD;
      busulfan, cladribine, and fludarabine, work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells, by stopping them from dividing, or by stopping them from&#xD;
      spreading. Adding venetoclax to the current standard of care stem cell transplant regimen of&#xD;
      busulfan, fludarabine, and cladribine may help to control high-risk acute myeloid leukemia or&#xD;
      myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To obtain preliminary evidence of efficacy as defined by 1-year progression free survival.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine safety of this regimen as per National Cancer Institute (NCI) toxicity&#xD;
      criteria.&#xD;
&#xD;
      II. To determine time to neutrophil and platelet engraftment. III. To determine incidence of&#xD;
      acute and chronic graft versus host disease (GVHD).&#xD;
&#xD;
      IV. To determine relapse incidence. V. To determine non-relapse mortality. VI. To determine&#xD;
      overall survival. VII. To determine graft versus host disease-relapse free survival (GRFS).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive venetoclax orally (PO) once daily (QD) on days -22 to -3, busulfan&#xD;
      intravenously (IV) over 3 hours on days -20, -13, -6, -5, -4, and -3, and fludarabine&#xD;
      phosphate (fludarabine) IV over 1 hour and cladribine IV over 2 hours on days -6 to -3 in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients then undergo stem cell&#xD;
      transplantation over 1-2 hours on day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 7 days, at engraftment, at&#xD;
      1, 3, 6, and 12 months, then annually for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year progression free survival (PFS)</measure>
    <time_frame>At 1 year post-transplant</time_frame>
    <description>The proportion of patients who are alive without disease relapse (PFS) at one year will be reported along with the corresponding 95% credible interval. Cox proportional hazards regression will be used to assess the association between PFS and clinical and treatment covariates of interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years post-transplant</time_frame>
    <description>OS will be calculated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus (vs.)-host disease-free, relapse-free survival (GRFS)</measure>
    <time_frame>Up to 3 years post-transplant</time_frame>
    <description>GRFS will be calculated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>From the time of transplant up to 3 years</time_frame>
    <description>The time to platelet engraftment will be calculated from the time of transplant and estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>From the time of transplant up to 3 years</time_frame>
    <description>The time to neutrophil engraftment will be calculated from the time of transplant and estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic graft-vs.-host disease (GvHD)</measure>
    <time_frame>Up to 3 years post-transplant</time_frame>
    <description>The cumulative incidence of acute and chronic GvHD with the competing risks of relapse and death will be estimated using the method of Gooley, and the method of Fine and Gray will be used to model the association between both parameters and clinical and treatment characteristics of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse and non-relapse mortality</measure>
    <time_frame>Up to 3 years post-transplant</time_frame>
    <description>The cumulative incidence of non-relapse mortality and relapse will also be assessed in a competing risks framework, with similar analyses performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 3 years post-transplant</time_frame>
    <description>Descriptive statistics will be used to summarize adverse events. The number and proportion of subjects with treatment emergent adverse events will be reported. All other safety parameters will be summarized using descriptive statistics or frequency counts. Graphical summaries will be used where appropriate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (venetoclax, busulfan, fludarabine, cladribine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive venetoclax PO QD on days -22 to -3, busulfan IV over 3 hours on days -20, -13, -6, -5, -4, and -3, and fludarabine phosphate IV over 1 hour and cladribine IV over 2 hours on days -6 to -3 in the absence of disease progression or unacceptable toxicity. Patients then undergo stem cell transplantation over 1-2 hours on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, busulfan, fludarabine, cladribine)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, busulfan, fludarabine, cladribine)</arm_group_label>
    <other_name>2-CdA</other_name>
    <other_name>2CDA</other_name>
    <other_name>CdA</other_name>
    <other_name>Cladribina</other_name>
    <other_name>Leustat</other_name>
    <other_name>Leustatin</other_name>
    <other_name>Leustatine</other_name>
    <other_name>RWJ-26251</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, busulfan, fludarabine, cladribine)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplantation</intervention_name>
    <description>Undergo stem cell transplantation</description>
    <arm_group_label>Treatment (venetoclax, busulfan, fludarabine, cladribine)</arm_group_label>
    <other_name>HCT</other_name>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
    <other_name>stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, busulfan, fludarabine, cladribine)</arm_group_label>
    <other_name>1,1'',1''''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N'', N''''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene Thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (venetoclax, busulfan, fludarabine, cladribine)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 and =&lt; 70 years&#xD;
&#xD;
          -  Patients with acute myeloid leukemia who have previously received induction therapy&#xD;
             and one of the following high-risk features:&#xD;
&#xD;
               -  ELN17 adverse risk prognostic group irrespective of remission status&#xD;
&#xD;
               -  Measurable residual disease positive (MRD +)&#xD;
&#xD;
               -  Not in complete remission including complete remission without count recovery&#xD;
                  (Cri), primary refractory, or relapsed disease or&#xD;
&#xD;
        Patients with myelodysplastic syndrome or chronic myelomonocytic leukemia (CMML) and one of&#xD;
        the following high-risk features:&#xD;
&#xD;
          -  Poor or very poor cytogenetic risk group as per Revised International Prognostic&#xD;
             Scoring System (IPSS-R)&#xD;
&#xD;
          -  Mutated P53 or Ras pathway genes (CBL, NRAS, KRAS, NF1, PTPN1) or DNMT 3a or ASXL1 or&#xD;
             RUNX1&#xD;
&#xD;
          -  IPSS-R &gt; 3.5 at diagnosis&#xD;
&#xD;
          -  &gt;= 5% bone marrow (BM) blasts at transplant&#xD;
&#xD;
               -  HLA-identical sibling or a 7/8 matched unrelated donor, or a haploidentical&#xD;
                  related donor available&#xD;
&#xD;
               -  Subject must voluntarily sign an informed consent&#xD;
&#xD;
               -  Female subjects of childbearing potential must have negative results for&#xD;
                  pregnancy test&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) &lt; 3.0 x upper limit&#xD;
                  of normal (ULN)&#xD;
&#xD;
               -  Bilirubin &lt; 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
                  non-hepatic origin)&#xD;
&#xD;
               -  Subject must have adequate renal function as demonstrated by a creatinine&#xD;
                  clearance &gt;= 50 mL/min; calculated by the Cockcroft Gault formula or measured by&#xD;
                  24 hours urine collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is known to be positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Subject has acute promyelocytic leukemia&#xD;
&#xD;
          -  Subject has known active central nervous system (CNS) involvement with acute&#xD;
             myeloblastic leukemia (AML)&#xD;
&#xD;
          -  Evidence of other clinically significant uncontrolled condition(s) including, but not&#xD;
             limited to:&#xD;
&#xD;
               -  Uncontrolled and/or active systemic infection (viral, bacterial or fungal)&#xD;
&#xD;
               -  Chronic hepatitis B virus (HBV) or hepatitis C (hepatitis C virus [HCV])&#xD;
                  requiring treatment. Note: subjects with serologic evidence of prior vaccination&#xD;
                  to HBV (i.e. hepatitis B surface [HBs] antigen negative-, anti-HBs antibody&#xD;
                  positive and anti-hepatitis B core [HBc] antibody negative) or positive anti-HBc&#xD;
                  antibody from intravenous immunoglobulins (IVIG) may participate&#xD;
&#xD;
          -  Cardiac history of congestive heart failure (CHF) requiring treatment or ejection&#xD;
             fraction &lt; 50% or unstable angina&#xD;
&#xD;
          -  Corrected diffusion capacity of the lung for carbon monoxide (DLCO) &lt; 65% or forced&#xD;
             expiratory volume in 1 second (FEV1) &lt; 65%&#xD;
&#xD;
          -  Treatment with any of the following within 7 days prior to the first dose of study&#xD;
             drug:&#xD;
&#xD;
               -  Steroid therapy for anti-neoplastic intent&#xD;
&#xD;
               -  Moderate or strong cytochrome P450 3A (CYP3A) inhibitors, moderate or strong&#xD;
                  CYP3A inducers. These agents may be used once venetoclax is discontinued&#xD;
&#xD;
          -  Administration or consumption of any of the following within 3 days prior to the first&#xD;
             dose of study drug:&#xD;
&#xD;
               -  Grapefruit or grapefruit products&#xD;
&#xD;
               -  Seville oranges (including marmalade containing Seville oranges)&#xD;
&#xD;
               -  Star fruit&#xD;
&#xD;
          -  Prior gemtuzumab ozogamicin and/or inotuzumab ozogamicin use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uday R Popat</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uday R. Popat</last_name>
    <phone>713-745-3055</phone>
    <email>upopat@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Uday R. Popat</last_name>
      <phone>713-745-3055</phone>
      <email>upopat@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Uday R. Popat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

